Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- The Historical Success of Growing Big Pharma from Small
- Derek Lowe submits: So that roughly linear production of new drugs by Pfizer PFE, as shown in yesterday's chart, is not an anomaly. As the Bernard Munos article I've been talking about says: Surprisingly, nothing that companies have done in the past 60 years has affected their rates of...
- External links 2009-12-13
- Sanofi-Aventis's 'Voluntary' Staff Departures
- Derek Lowe submits: Sanofi Aventis SNY said "no layoffs" in the company's announcement yesterday, but is instead counting on "voluntary staff departures". Here's the press release, courtesy of Fierce Biotech, notable for its relentless insistence on not capitalizing the name of the company. I'm not sure...
- External links 2009-07-01
- Ariad Pharma: Professors Patent Pathways and Possibly Profit?
- Derek Lowe submits: Nature Biotechnology has a good wrap-up of the Ariad ARIA patent case, and it includes some insights into the whole "patent the pathway and profit" mindset. That was the heart of Ariad's strategy: they licensed a patent on NF-kappaB from Harvard, MIT, and the Whitehead institute,...
- External links 2009-06-18
- A View from Pfizer's Corner Offices
- Derek Lowe submits: There's a good article from Lee Howard up at The Day (the New London/Groton newspaper) on the changes going on at Pfizer. It's the story according to management, though, which is worth having for its compare-and-contrast uses: Despite the looming uncertainty, according to company...
- External links 2009-06-18
- Lilly's Alzheimer Drug Lawsuits Just Got Messier
- Derek Lowe submits: Well, this doesn't look good for Lilly LLY. A huge pile of court documents has been unsealed in the ongoing lawsuits about Zyprexa's off-label promotion. The company has already paid some serious fines, and is now fighting it out with insurance companies and other plaintiffs who...
- External links 2009-06-15
- Merck and AstraZeneca: An Uncommon Deal Indeed
- Derek Lowe submits: Well, the ASCO meeting has been roaring along, with dozens of press releases coming out. (Go to Google News and type that acronym in if you want to get the full experience.) They range from the pretty-interesting to the despair-inducing, but one bit of news struck...
- External links 2009-06-02
- Glaxo Does a Deuterium Deal
- Derek Lowe submits: Well, there's someone who certainly believes in the deuterated-drug idea! GlaxoSmithKline GSK has announced today that they've signed a deal with Concert Pharmaceuticals to develop these. There's a $35 million payment upfront, which I'm sure will be welcome in this climate, and various milestone and royalty...
- External links 2009-06-02
- J&J's New Acquisition Strategy Makes Sense
- Derek Lowe submits: Johnson & Johnson's JNJ CEO has given an interview to the Financial Times explaining his company's strategy with acquisitions. And right now, that strategy is. ..not to make acquisitions. They see partnerships as making a lot more sense: “The cost of developing compounds...
- External links 2009-10-29
- Pfizer's New Look
- Derek Lowe submits: The company has issued a press release detailing which sites are staying, and which are leaving: Pfizer PFE will have five main research sites that will serve as central hubs for research activities in BioTherapeutics, PharmaTherapeutics and Vaccines. These sites are: Cambridge, Mass.;...
- External links 2009-11-10
- Another Look at Pfizer's Recent Moves
- Derek Lowe submits: Pharmaconduct.org has another look at Pfizer's PFE announcement Monday, and tries to address some of the many unanswered questions left open by the company's press release. One thing that struck me and many others is that the company talked about "moving a number of functions" from...
- External links 2009-11-10
- Pfizer's Chemistry Head Count: Lower than Before the Wyeth Merger
- Derek Lowe submits: A reader who's unfortunately in a position to know the details sends along some numbers on Pfizer's PFE chemistry shakeout. According to his figures, Pfizer (pre-Wyeth merger) had about 900 chemists. The Wyeth deal brought in about 350, but no one expected the merged department to...
- External links 2009-11-11
- Pfizer: What It Will Look Like a Year from Now
- Derek Lowe submits: The Wall Street Journal's Health Blog got a chance to ask the higher-ups at Pfizer PFE what their R&D will look like a year from now. Their understandably not too-in-depth answers are here: Decentralized research units, with some functions run company-wide, and this quote: "There are...
- External links 2009-10-20
- Justice Department Makes 2.3 Billion Dollar Example of Pfizer's Marketing Practices
- Derek Lowe submits: No sooner do I write another post about pharma marketing than Pfizer PFE finds itself paying 3.2 billion dollars in fines for doing it improperly. 1.2 billion of that is a criminal penalty, and needless to say, they've set the current record. The...
- External links 2009-09-03
- Eli Lilly Braces for Reorganization Moves
- Derek Lowe submits: The latest re-org announcement is from Eli Lilly LLY. The company is getting braced for the Zyprexa patent expiration (and the possibility that Prasugrel and others won't be able to make up for as much lost revenue as they thought). Their target is a 14% head...
- External links 2009-09-15
- Big Pharma's Future Death Spiral?
- Derek Lowe submits: One of this blog's regular correspondents has just been attending a chemistry outsourcing conference program here, and heard a very interesting talk from Stefan Loren of a Baltimore investment advisory firm, Westwicke Partners. Loren's a product of the Sharpless lab, who went on to Abbott ABT,...
- External links 2009-09-18
- More on Pfizer's Layoffs
- Derek Lowe submits: Pfizer's made an announcement about the dimensions of its research cuts - 5 to 8%, which means about 500 to 800 scientists this year. These are (for the most part, I presume) the "not in our current research areas" people from the company's recent re-work of...
- External links 2009-01-13
- Eli Lilly Pays the Price for Off-Label Promotion
- Derek Lowe submits: Eli Lilly LLY has been in trouble for some time now regarding off-label promotion of their antipsychotic Zyprexa – specifically, their sales reps seem to have gone around saying that it was useful in treating the dementia of Alzheimer’s patients, although there was no FDA approval...
- External links 2009-01-15
- Goldman Sachs: Brewing a New Drug Research Model?
- Derek Lowe submits: Now, here’s an odd item from the Financial Times registration required: Goldman Sachs is in talks to provide hundreds of millions of dollars of funding to a large pharmaceutical company, in the first evidence of a new business model for the sector that...
- External links 2008-12-10
- Wyeth vs. Conte: Are Big Pharmas Now Liable for Generics?
- Derek Lowe submits: There was a legal ruling last week in California that we’re going to hear a lot more of in this business. Conte v. Wyeth WYE. This case involved metaclopramide, which was sold by Wyeth as Reglan before going off-patent in 1982. The plaintiff had been prescribed...
- External links 2008-11-18
- Pfizer's New Structure: Has The Company Learned From Past Merger Mistakes?
- Derek Lowe submits: So Pfizer's PFE announced its post-Wyeth structure, and on the face of it, the plan makes as much sense as you can make of such a massive organization. The big divide is between small molecules and biologics, which makes sense - the two of them have...
- External links 2009-04-08
- << Previous
- page 1 of 2
- Next >>
Presented by American Express